Gilead Sciences — Feb 10, 2026 release

RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE (1) (unaudited) (in millions, except percentages and per share amounts) Provided February 10, 2026 Projected product gross margin GAAP to non-GAAP reconciliation: GAAP projected product gross margin ~ 79.0% Acquisition-related expenses ~ 8.0% Non-GAAP projected product gross margin ~ 87.0% Projected operating income GAAP to non-GAAP reconciliation: GAAP projected operating income $11,400 - $11,900 Acquisition-related and restructuring expenses ~ 2,400 Non-GAAP projected operating income $13,800 - $14,300 Projected effective tax rate GAAP to non-GAAP reconciliation: GAAP projected effective tax rate ~ 21% Income tax effect of above non-GAAP adjustments, and discrete and related tax adjustments (~ 1%) Non-GAAP projected effective tax rate ~ 20% Projected diluted EPS GAAP to non-GAAP reconciliation: GAAP projected diluted EPS $6.75 - $7.15 Acquisition-related and restructuring expenses, and discrete and related tax adjustments ~ 1.70 Non-GAAP projected diluted EPS $8.45 - $8.85 ________________________________ (1)     Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current perio